Pharming (PHAR) Income from Non-Controlling Interests (2025)
Pharming's (PHAR) quarterly Income from Non-Controlling Interests came in at -$313000.0 in Q4 2025, down 285.21% on a QoQ basis from $169000.0 in Q3 2025.
Pharming (PHAR) Income from Non-Controlling Interests (2025) Analysis & Trends
Pharming (PHAR) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$313000.0 in Q4 2025.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$313000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$626000.0 (changed N/A YoY) and the FY2025 annual result came in at -$313000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests slipped to -$313000.0 in Q4 2025, from $169000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $169000.0 in Q3 2025 to a low of -$313000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -313,000.00 |
| Sep 30, 2025 | 169,000.00 |
| Jun 30, 2025 | -313,000.00 |
| Mar 31, 2025 | -169,000.00 |